Chemical formula: C₁₇H₁₇ClN₆O₃ Molecular mass: 388.808 g/mol PubChem compound: 969472
Eszopiclone is indicated for the treatment of insomnia. The mechanism of action of eszopiclone as a hypnotic is unclear; however, its effect could be related to its interaction with GABA-receptor complexes at binding domains located close to or allosterically coupled to benzodiazepine receptors.
This medicinal substance has been classified in the anatomical therapeutic chemical (ATC) classification according to its main therapeutic use as follows:
| ATC code | Group title | Classification |
|---|---|---|
| N05CF04 | Eszopiclone | N Nervous system → N05 Psycholeptics → N05C Hypnotics and sedatives → N05CF Benzodiazepine related drugs |
Competent medicine agencies globally have authorized commercialization of this active ingredient according to these medication package inserts (MPIs):
| Title | Information Source | Document Type | |
|---|---|---|---|
| LUNESTA Coated tablet | FDA, National Drug Code (US) | MPI, US: SPL/PLR |
Eszopiclone is an active ingredient of these brands:
United States (US)Austria (AT)Canada (CA)Ecuador (EC)Estonia (EE)Germany (DE)Japan (JP)Lithuania (LT)Poland (PL)Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide. |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
